Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate Regimen and Its Effect on Liver Steatosis Assessed by Fibroscan
Open Access
Abstract
Background: Antiretroviral therapy has transformed HIV infection from a fatal disease to a chronic and manageable condition, but increasing health issues beyond acquired immunodeficiency syndrome, such as metabolic, liver, and cardiovascular diseases, have been observed. Furthermore, the increasing prevalence of HIV strains resistant to older antiretroviral regimens has necessitated a re-evaluation of treatment strategies. Methods: We performed a retrospective, observational study to evaluate the long-term outcomes of an antiretroviral switch from a non-nucleoside reverse transcriptase inhibitor-based to bictegravir-based regimen; this study aimed to assess the impact of this antiretroviral switch on treatment adherence, the safety profile, and virologic outcomes. The secondary objectives were to analyze the changes in lipid, kidney function, liver function, and anthropometric parameters after switching. Results: A total of 25 patients were included in this analysis; virologic suppression was maintained over time, with 100% of patients demonstrating undetectable viral loads at 6, 12, 24, and 36 months. In parallel, a significant increase in CD4+ cell count was observed after switching. No significant differences were observed compared to the previous therapy regarding anthropometric parameters or laboratory parameters. However, a significant reduction in liver steatosis, as assessed by Fibroscan, was observed. Conclusions: bictegravir-based regimens are a valid therapeutic option for people living with HIV, particularly for those with metabolic comorbidities.Keywords
Funding Information
- Gilead
This publication has 47 references indexed in Scilit:
- Next-generation sequencing and drug resistance mutations of HIV-1 subtypes in people living with HIV in Sicily, Italy, 2021–2023Journal of Global Antimicrobial Resistance, 2024
- Steatotic liver diseaseThe Lancet, 2024
- Inclusive healthcare in light of the new MASLD guidelines: Should people living with HIV be screened for liver fibrosis?Journal of Hepatology, 2024
- TyG index is positively associated with HOMA-IR in cholelithiasis patients with insulin resistance: Based on a retrospective observational studyAsian Journal of Surgery, 2024
- Biktarvy for the treatment of HIV infection: Progress and prospectsBiochemical Pharmacology, 2023
- Pillars of long-term antiretroviral therapy successPharmacological Research, 2023
- Interactions of Antiretroviral Drugs with Food, Beverages, Dietary Supplements, and Alcohol: A Systematic Review and Meta-analysesAIDS and Behavior, 2022
- Effect of hepatic steatosis and associated metabolic comorbidities on health‐related quality of life in people living with HIVHepatology Communications, 2022
- Impact of Implementing a “FIB‐4 First” Strategy on a Pathway for Patients With NAFLD Referred From Primary CareHepatology Communications, 2019
- The Use of Liver Biopsy in Nonalcoholic Fatty Liver DiseaseClinics in Liver Disease, 2018